The FDA recently approved the second cellular immunotherapy to treat certain adult patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved ciltacabtagene autoleucel (Carvykti) to treat adult patients with relapsed...
The FDA approved the targeted immunotherapy tebentafusp-tebn for certain adult patients with uveal melanoma. The U.S. Food and Drug Administration (FDA) has approved tebentafusp-tebn (Kimmtrak), a fusion protein that acts as an immunotherapy, for...
The FDA approved an immune checkpoint inhibitor for patients with stage IIB or IIC melanoma following surgical removal of their tumor. The U.S. Food and Drug Administration (FDA) approved the immunotherapeutic pembrolizumab (Keytruda) for...
The FDA approved a monoclonal antibody combined with chemotherapy TO TREAT certain childhood blood cancers that express the protein CD20. The U.S. Food and Drug Administration (FDA) has approved rituximab (Rituxan), in combination with...
The U.S. FDA approved a new combination of existing drugs to treat certain patients with multiple myeloma The U.S. Food and Drug Administration (FDA) approved a new combination therapy for multiple myeloma in adult...
A new drug approved by the U.S. FDA may help surgeons find cancer more easily and reduce the likelihood of leaving cancer cells behind The U.S. Food and Drug Administration (FDA) approved the imaging...
The U.S. FDA approved the first treatment for malignant perivascular epithelioid cell tumor The U.S. Food and Drug Administration (FDA) approved sirolimus protein-bound particles for injectable suspension (albumin-bound) (Fyarro) to treat adult patients with...
The FDA has approved an immunotherapy known as immune checkpoint inhibition for the treatment of certain patients with kidney cancer. The U.S. Food and Drug Administration (FDA) has approved the immunotherapeutic pembrolizumab (Keytruda) for...
THE FDA GRANTED ACCELERATED APPROVAL TO A TARGETED THERAPY FOR PATIENTS WITH CML RESISTANT TO OTHER THERAPEUTICS The U.S. Food and Drug Administration (FDA) approved the drug asciminib (Scemblix) for certain patients with Philadelphia...
THE FDA APPROVED THE FIRST ADJUVANT IMMUNOTHERAPY FOR EARLY LUNG CANCER The U.S. Food and Drug Administration (FDA) granted expanded approval to atezolizumab (Tecentriq) to include the treatment of certain patients with early non-small...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now